Are serum lithium levels related to the polarity of recurrence in bipolar disorders?: Evidence from a multicenter trial

International Clinical Psychopharmacology

Volumn 22, Issue 3, 2007, Pages 125-131

  Kleindienst, Nikolaus ^a,b   Severus, Wolfram Emanuel ^a   Greil, Waldemar ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c Psychiatric Private Clinic Sanatorium Kilchberg   (Switzerland)

Author keywords

Bipolar disorder; Clinical trial; Dose response relationship; Drug; Lithium

Indexed keywords

LITHIUM;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; INTERVENTION STUDY; LITHIUM BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; SYMPTOMATOLOGY;

ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RISK FACTORS;

EID: 34147115692     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224788.21406.c8     Document Type: Article

References (32)

1. Angst J (1981). Clinical indications for a prophylactic treatment of depression. Adv Biol Psychiatr 7:218-229.
2. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392-400.
3. Calabrese J, Rapport DJ, Shelton MD (2002). Pursuit of the ideal mood stabilizer: time to give up and move to combination trials. In: Maj M, Akiskal HS, López-Ibor JJ, Sartorius N, editors. Bipolar disorder. (WPA series: Evidence and experience in psychiatry). Chichester, New York: Wiley. pp. 222-224.
4. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. (2003). A Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013-1024.
5. Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, et al. (2004). Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 15:957-963.
6. Coppen A, Montgomery SA, Gupta RK, Bailey JE (1976). A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry 128:479-485.
7. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771.
8. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, et al. (1989). Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 321:1489-1493.
9. Gershon S, Soares JC (1997). Current therapeutic profile of lithium. Arch Gen Psychiatry 54:16-20.
10. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432-441.
11. Greenspan K, Goodwin FK, Bunney WE, Durell J (1968). Lithium ion retention and distribution. Patterns during acute mania and normothymia. Arch Gen Psychiatry 19:664-673.
12. Greil W, Kleindienst N (2003). Concepts in the treatment of bipolar disorder. Acta Psychiatr Scand Suppl 418:41-46.
13. Greil W, Ludwig-Mayerhofer W, Steller B, Czernik A, Giedke H, Müller-Oerlinghausen B, et al. (1993). The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord 28:257-265.
14. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, et al. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomized study. J Affect Disord 43:151-161.
15. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18:455-460.
16. Hakim C, Pichot D (1972). Le traitement prophylactique de la psychose maniaco-dé pressive par le carbonate de lithium. Intérêt théorique et pratique de l'é tude des variations de la concentration plasmatique (Prophylactic treatment of manic-depressive psychoses with lithium carbonate. Theoretical and practical value of the study of variations of plasma concentrations) [in French]. Ann Med Psychol 130:238-246.
17. Himmelhoch JM, Neil JF (1980). Lithium therapy in combination with othter forms of treatment. In: Johnson FN, editor. Handbook of lithium therapy. Lancaster, UK: MTP Press. pp. 1175-1179.
18. Ketter TA, Calabrese JR (2002). Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 63:146-151.
19. Kleindienst N, Greil W (2004). Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J Clin Psychiatry 65:966-974.
20. Kleindienst N, Severus WE, Greil W (2005). Is polarity of recurrence related to serum lithium level in patients with bipolar disorder? Eur Arch Psychiatry Clin Neurosci 255:72-74.
21. Kukopoulos A, Minnai G, Müller-Oerlinghausen B (1985). The influence of mania and depression on the pharmacokinetics of lithium. A longitudinal single-case study. J Affect Disord 2:159-166.
22. Kukopulos A, Reginaldi D (1978). Variations of serum lithium concentrations correlated with the phases of manic-depressive psychosis. Agressiologie 19:219-222.
23. Licht RW (2002). Limits of the applicability and generalizability of drug trials in mania. Bipolar Disord 4 (Suppl 1):66-68.
24. Licht RW (2005). How representative are patients in drug trials on mania? Eur Psychiatry 20 (Suppl 1):130.
25. Lusznat RM, Murphy DP, Nunn CM (1988). Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 153:198-204.
26. Maj M, Starace F, Nolfe G, Kemali D (1986). Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 19:420-423.
27. Nilsson A, Axelsson R (1989). Psychopathology during long-term lithium treatment of patients with major affective disorders. Acta Psychiatr Scand 80:375-388.
28. Sachs GS, Renshaw PF, Lafer B, Stoll AL, Guimaraes AR, Rosenbaum JF, et al. (1995). Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Biol Psychiatry 38:422-428.
29. Severus WE, Grunze H, Kleindienst N, Frangou S, Möller HJ (2005). Is the prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level? J Clin Psychopharmacol 25:457-462.
30. Stallone F, Shelley E, Mendlewicz J, Fieve RR (1973). The use of lithium in affective disorders. 3. A double-blind study of prophylaxis in bipolar illness. Am J Psychiatry 130:1006-1010.
31. Tohen M, Marneros A, Greil W, Sachs GS, Yatham LN, Müller- Oerlinghausen B, et al. (2005). Olanzapine versus lithium in relapse/recurrence prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Am J Psychiatry 162:1281-1290.
32. Vestergaard P, Licht RW, Brodersen A, Rasmussen NA, Christensen H, Arngrim T, et al. (1998). Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand 98:310-315.